• Recruiting

NCT04268199: Phase 2: Exploring Self-Administration of Chemo in the Home Environment (EASE)

NCT04268199: Phase 2: A Multicentre, Non-Blinded Study Exploring Self-Administration of Chemotherapy in the Home Environment (EASE)

AHS Cancer Control Alberta

NCT04268199: Phase 2: A Multicentre, Non-Blinded Study Exploring Self-Administration of Chemotherapy in the Home Environment (EASE)


This study is to see if the standard of care subcutaneous injection of bortezomib can safely be administered at home by the patient or caregiver. All tests and assessments are based on standard of care procedures.


Sponsor

AHS Cancer Control Alberta


Collaborator

Tom Baker Cancer Centre

 

ClinicalTrials.gov Identifier: NCT04268199

Official Title: A Multicentre, Non-Blinded Study Exploring Self-Administration of Chemotherapy in the Home Environment

First Posted : February 13, 2020

Click here to see details on ClinicalTrials.gov

 

Drug: Bortezomib Injection

 

Locations

Canada, Alberta



Posts Archive